Replies to post #250075 on Biotech Values

[DewDiligence]

APLS management is making excuses vis-à-vis the Syfovre launch, but the real problem (IMO) is that the drug simply isn’t that good:

https://www.fiercepharma.com/pharma/apellis-cites-current-challenges-syfovre-launch-bright-prospects-long-term

See #msg-171260849 for related info.

[DewDiligence]

CHMP rejects APLS’ Syfovre again—APLS plans appeal:

https://www.globenewswire.com/news-release/2024/06/28/2905763/0/en/Apellis-Plans-to-Seek-Re-Examination-Following-Negative-CHMP-Opinion-for-Pegcetacoplan-for-Geographic-Atrophy-GA-in-the-EU.html

In short, the CHMP is not convinced that Syfovre offers patients a meaningful clinical benefit.

I’ve long been bearish on APLS’ Syfovre—see, for instance, #msg-171260849.